Skip to main content
Clinical Trials/NCT00164801
NCT00164801TerminatedNot Applicable

Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients

Chinese University of Hong Kong1 site in 1 country60 target enrollmentStarted: November 1, 2004Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
60
Locations
1
Primary Endpoint
Esophageal sensory and pain thresholds

Study Overview

Brief Summary

The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy
  • •Age between 18-70
  • •Gastroesophageal reflux disease
  • •Psychiatric illness
  • •Cerebrovascular accident
  • •Active peptic ulceration
  • •Heart failure or cardiac bradyarrhythmia
  • •Pregnancy or lactating female
  • •Previous hypersensitivity to muscle relaxant

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Esophageal sensory and pain thresholds

Secondary Outcomes

  • Symptom severity of chest pain at the end of treatment
  • Evoked potential responses

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials